Skip to main content
Clinical Trials/CTRI/2021/07/035281
CTRI/2021/07/035281Active, not recruiting未知

Evaluating the Use of Blood based Real Time Polymerase Chain Reaction Testing for Early Detection and Monitoring of Mucormycosis.

Datar Cancer Genetics Private Limited0 sites0 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
未知
Status
Active, not recruiting

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Inclusion Criteria

  • ââ?¬Â¢High risk patients (patients with prolonged severe neutropenia, receiving corticosteroids or T-cell suppressor, recipients of allogeneic Hematopoietic stem-cell transplantation (HSCT), or inherited severe immunodeficiency)
  • ââ?¬Â¢Patients with other predisposing factors of invasive mould disease (Uncontrolled blood sugars, known diabetic on steroids , Acquired immunodeficiency syndrome (AIDS), haematological malignancies or solid tumours, prolonged Intensive Care Unit, or hospital stay abnormal D Dimer test).
  • ââ?¬Â¢Patients already diagnosed with probable or proven mucormycosis irrespective of underlying conditions, including patients referred from other centers.

Exclusion Criteria

  • ââ?¬Â¢Presence of any medical condition that would not allow collection of blood samples for the Real-time polymerase chain reaction test.
  • ââ?¬Â¢History of documented, successfully treated, prior Mucormycosis.

Investigators

Similar Trials